Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2

Journal of the American Heart Association

Volumn 4, Issue 2, 2015, Pages

  Fenning, Robert S ^a   Burgert, Mark E ^b   Hamamdzic, Damir ^a   Peyster, Eliot G ^a   Mohler, Emile R ^a   Kangovi, Shreya ^a   Jucker, Beat M ^b   Lenhard, Stephen C ^b   Macphee, Colin H ^b   Wilensky, Robert L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Peripheral vascular disease; Arteriosclerosis; Coronary disease; Darapladib; Inflammation; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DARAPLADIB; GLUCOSE; BENZALDEHYDE DERIVATIVE; OXIME; PHOSPHOLIPASE A2 INHIBITOR;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE SEVERITY; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFLAMMATION; MACROPHAGE MIGRATION; MALE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PIG;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; AORTA, ABDOMINAL; ATHEROSCLEROSIS; BENZALDEHYDES; CORONARY VESSELS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; INFLAMMATION; MACROPHAGES; MALE; OXIMES; PHOSPHOLIPASE A2 INHIBITORS; PLAQUE, ATHEROSCLEROTIC; SWINE;

EID: 85005900827     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001477     Document Type: Article

References (34)

1. DeBakey ME, Lawrie GM, Glaeser DH. Patterns of atherosclerosis and their surgical significance. Ann Surg. 1985;201:115-131.
2. Criqui MH, Kamineni A, Allison MA, Ix JH, Carr JJ, Cushman M, Detrano R, Post W, Wong ND. Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:2289-2296.
3. Mohler ER III, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A, Macphee C, Llano R, Pelchovitz D, Mainigi SK, Osman H, Hallman T, Steplewski K, Gertz Z, Lu MM, Wilensky RL. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol. 2008;28:850-855.
4. Granada JF, Kaluza GL, Wilensky RL, Biedermann BC, Schwartz RS, Falk E. Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention. 2009;5:140-148.
5. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol. 2005;16:442-446.
6. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER III, Macphee C, Zalewski A, Postle A, Wilensky RL. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191:54-62.
7. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066.
8. The SI. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702-1711.
9. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
10. Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, James CH, Greaves DR, Patel L. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26:1837-1844.
11. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, Hamann J. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004;55:655-666.
12. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55:221-227.
13. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscl Throm Vas. 2008;28:1897-1908.
14. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866.
15. Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, Kawarabayashi T, Fukuda D, Yoshikawa J. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005;45:1594-1599.
16. Okura H, Asawa K, Kubo T, Taguchi H, Toda I, Yoshiyama M, Yoshikawa J, Yoshida K. Incidence and predictors of plaque rupture in the peripheral arteries. Circ Cardiovasc Interv. 2010;3:63-70.
17. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation. 2008;117:993-1002.
18. Passerini AG, Polacek DC, Shi C, Francesco NM, Manduchi E, Grant GR, Pritchard WF, Powell S, Chang GY, Stoeckert CJ Jr, Davies PF. Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta. Proc Natl Acad Sci USA. 2004;101:2482-2487.
19. Cheng C, Helderman F, Tempel D, Segers D, Hierck B, Poelmann R, van Tol A, Duncker DJ, Robbers-Visser D, Ursem NT, van Haperen R, Wentzel JJ, Gijsen F, van der Steen AF, de Crom R, Krams R. Large variations in absolute wall shear stress levels within one species and between species. Atherosclerosis. 2007;195:225-235.
20. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49:2379-2393.
21. Haimovici H, Maier N. Fate of Aortic Homografts in Canine Atherosclerosis. 3. Study of Fresh Abdominal and Thoracic Aortic Implants into Thoracic Aorta:Role of Tissue Susceptibility in Atherogenesis. Arch Surg. 1964;89:961-969.
22. Bahls M, Bidwell CA, Hu J, Krueger CG, Reed JD, Tellez A, Kaluza GL, Granada JF, Van Alstine WG, Newcomer SC. Gene expression differences in healthy brachial and femoral arteries of Rapacz familial hypercholesterolemic swine. Physiol Genomics. 2011;43:781-788.
23. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke. 2007;38:2698-2705.
24. Levula M, Oksala N, Airla N, Zeitlin R, Salenius JP, Jarvinen O, Venermo M, Partio T, Saarinen J, Somppi T, Suominen V, Virkkunen J, Hautalahti J, Laaksonen R, Kahonen M, Mennander A, Kytomaki L, Soini JT, Parkkinen J, Pelto-Huikko M, Lehtimaki T. Genes involved in systemic and arterial bed dependent atherosclerosis-Tampere Vascular study. PLoS ONE. 2012;7:e33787.
25. Padilla J, Jenkins NT, Lee S, Zhang H, Cui J, Zuidema MY, Zhang C, Hill MA, Perfield JW II, Ibdah JA, Booth FW, Davis JW, Laughlin MH, Rector RS. Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine. Physiol Genomics. 2013;45:434-446.
26. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: siteselective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004;24:12-22.
27. Epps KC, Wilensky RL. Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011;269:94-106.
28. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006;26:631-636.
29. Saremi A, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2010;33:2642-2647.
30. Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA, de Lemos JA. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem. 2008;54:1975-1981.
31. Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, Brannan SP, Tarka EA, Shaddinger BC, Sarov-Blat L, Matthews P, Subramanian S, Farkouh M, Fayad ZA. Effect of Treatment for 12 weeks with Rilapladib, a Lipoproteinassociated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed with 18F-Fluorodeoxyglucose-PET Imaging. J Am Coll Cardiol. 2014;63:86-88.
32. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
33. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344-1353.
34. O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; Investigators S-T. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312:1006-1015.